Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
- Revenue in USD (TTM)30.07bn
- Net income in USD2.09bn
- Incorporated1925
- Employees47.35k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Mergers & acquisitions
| Acquired company | 4502:TYO since announced | Transaction value |
|---|---|---|
| Nimbus Lakshmi Inc | 2.96% | 6.00bn |
| Shionogi & Co Ltd-Intuniv & Vyvanse Manufacturing & Sales Business | 8.76% | -- |
Data delayed at least 20 minutes, as of Feb 03 2023 06:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gartner Inc | 5.28bn | 760.34m | 27.02bn | 16.60k | 36.88 | -- | 28.29 | 5.12 | 9.27 | 9.27 | 64.37 | -0.8201 | 0.7807 | -- | 5.11 | 317,918.80 | 11.25 | 4.12 | 20.19 | 7.06 | 69.34 | 65.00 | 14.41 | 6.65 | -- | 15.86 | 1.03 | -- | 15.48 | 14.13 | 197.50 | 32.60 | 3.71 | -- |
| Alnylam Pharmaceuticals, Inc. | 960.92m | -1.18bn | 28.71bn | 1.67k | -- | -- | -- | 29.88 | -9.77 | -9.77 | 7.95 | -0.5499 | 0.2743 | 1.45 | 6.86 | 577,127.90 | -33.74 | -32.56 | -42.04 | -37.94 | 83.85 | -- | -123.02 | -223.64 | 3.33 | -2.76 | 1.07 | -- | 71.31 | 78.07 | 0.6358 | -- | 3.42 | -- |
| DuPont de Nemours Inc | 14.18bn | 1.16bn | 36.26bn | 28.00k | 31.89 | 1.46 | 14.55 | 2.56 | 2.29 | 3.63 | 27.84 | 50.15 | 0.3148 | 3.54 | 5.49 | 506,571.40 | 2.71 | -0.2227 | 3.11 | -0.2892 | 35.05 | 31.60 | 8.62 | -1.61 | 1.99 | 5.11 | 0.3173 | -- | 16.15 | -19.13 | 172.14 | -15.09 | -25.20 | -26.30 |
| Iqvia Holdings Inc | 14.31bn | 1.18bn | 44.05bn | 85.00k | 38.60 | 8.24 | 19.77 | 3.08 | 6.15 | 6.15 | 74.43 | 28.78 | 0.593 | -- | 5.76 | 181,101.30 | 4.94 | 1.77 | 6.25 | 2.14 | 34.72 | 34.30 | 8.34 | 3.64 | -- | 5.16 | 0.6986 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| Takeda Pharmaceutical Co Ltd (ADR) | 30.07bn | 2.09bn | 51.30bn | 47.35k | 23.70 | 1.05 | 7.24 | 1.71 | 0.6738 | 0.6738 | 9.67 | 15.14 | 0.3011 | 1.43 | 5.54 | 635,151.40 | 2.10 | 1.86 | 2.48 | 2.24 | 68.50 | 68.85 | 6.96 | 6.98 | 0.746 | 3.41 | 0.4097 | 123.94 | 11.61 | 15.56 | -38.81 | 14.89 | 10.68 | 0.00 |
| Moderna Inc | 21.39bn | 11.77bn | 66.56bn | 2.70k | 6.26 | 3.73 | 5.50 | 3.11 | 27.65 | 27.65 | 50.69 | 46.49 | 0.9106 | 2.93 | 7.33 | 7,922,222.00 | 50.09 | 41.17 | 77.88 | 66.78 | 79.20 | -- | 55.00 | 52.35 | 1.80 | -- | 0.0599 | 0.00 | 2,199.12 | 179.44 | 1,733.33 | -- | 53.67 | -- |
Data as of Feb 03 2023. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: US Dollar USD
0.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mondrian Investment Partners Ltd.as of 30 Sep 2022 | 4.75m | 0.15% |
| Clal Pension & Provident Funds Ltd.as of 30 Sep 2022 | 4.34m | 0.14% |
| Parametric Portfolio Associates LLCas of 30 Sep 2022 | 4.21m | 0.13% |
| Macquarie Investment Management Business Trustas of 30 Sep 2022 | 3.99m | 0.13% |
| Renaissance Technologies LLCas of 30 Sep 2022 | 2.85m | 0.09% |
| Aperio Group LLCas of 30 Sep 2022 | 2.23m | 0.07% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2022 | 2.19m | 0.07% |
| Goldman Sachs Asset Management LPas of 30 Sep 2022 | 1.97m | 0.06% |
| Strategic Advisers LLCas of 30 Sep 2022 | 1.96m | 0.06% |
| Brandes Investment Partners LPas of 30 Sep 2022 | 1.87m | 0.06% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
